Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants (Part 1) and A Phase IIa, Open-Label Study to Evaluate a Range of Pharmacodynamic Effects of a Single Intravenous Dose of ELE-101 in Patients With Major Depressive Disorder (Part 2).

To see complete record on, please visit this link

Id: NCT05434156

Organisation Name: Eleusis Therapeutics

Overal Status: Recruiting

Start Date: October 27, 2022

Last Update: November 14, 2022

Lead Sponsor: Eleusis Therapeutics

Brief Summary: A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).

  • Healthy Volunteers
  • Major Depressive Disorder
  • Depression

Total execution time in seconds: 0.20311594009399